StocksMedium•1 October 2026•
1 min read
Edwards Lifesciences Wins FDA Approval for First Pediatric Surgical Pulmonary Valve
Key Facts
1Edwards Lifesciences received FDA approval for the AUTUS Size-Adjustable Valve.
2The AUTUS valve is the first FDA-approved surgical pulmonary valve designed specifically for pediatric anatomy.
Edwards Lifesciences received FDA approval for the AUTUS Size-Adjustable Valve. Business Wire reported that the device is the first FDA-approved surgical pulmonary valve designed specifically for pediatric anatomy, targeting the specific needs of pediatric patients with congenital heart disease.
The AUTUS valve is engineered to be size-adjustable to accommodate growing pediatric anatomy, which may reduce the frequency of valve replacement procedures. Regarding equity performance, EW closed at $86.32 on September 30, 2026, after reaching a day high of $87.49 and a low of $85.72 during the session.